Recalled Drug Consists of Another Impurity, Says the FDA

Kathleen Kinder
Kathleen Kinder

Updated · Sep 17, 2018

SHARE:

News.Market.us is supported by its audience. When you purchase through links on our site, we may earn an affiliate commission. Learn more.
close
Advertiser Disclosure

At Market.us News, we strive to bring you the most accurate and up-to-date information by utilizing a variety of resources, including paid and free sources, primary research, and phone interviews. Our data is available to the public free of charge, and we encourage you to use it to inform your personal or business decisions. If you choose to republish our data on your own website, we simply ask that you provide a proper citation or link back to the respective page on Market.us News. We appreciate your support and look forward to continuing to provide valuable insights for our audience.

According to the latest report, the United States Food and Drug Administration has found another impurity in a bunch of drugs that were recalled sometime back. These valsartan-based drugs were tested positive for an unexpected impurity, which was not among the reasons for the primary recall. The drugs are being made by Torrent Pharmaceuticals. N-nitrosodimethylamine, or NDMA was found in these drugs. This impurity can be cancerous according to the US Environmental Protection Agency. Upon this finding, several drugs that do contain valsartan were recalled by the FDA. It should be noted that all valsartan drugs are not being recalled, and FDA keeps an updated list.

N-nitrosodimethylamine, or NDMA is not a component that is intentionally added to the drugs. On the other hand, it’s an organic component that may be introduced to the drugs as a part of some chemical reactions. Manufacturing of some pesticides and processing of fish can result in the creation of this component, which is also used as a part of rocket fuel. However, the question how N-nitrosodimethylamine, or NDMA made it to these drugs remains. According to the latest reports, the three drugs from Torrent Pharmaceuticals also contain N-Nitrosodiethylamine, or NDEA, which is another carcinogen.

The FDA has given proper instructions on how to deal with things if you are consuming one of the recalled drugs. FDA recommends that you should talk to your doctor before making changes to the routine. Until a viable replacement is given, consumption of the recalled medicine should continue. “As we continue to investigate the root cause of the impurities found in products that contain valsartan, our scientists are testing these products to better understand these impurities and to ensure they’re not present in other products. We’re also taking steps to make sure we’re providing stringent oversight of manufacturing processes to reduce the likelihood that impurities could be introduced into other products”, said FDA.

SHARE:
Kathleen Kinder

Kathleen Kinder

With over 4 years of experience in the research industry, Kathleen is generally engrossed in market consulting projects, catering primarily to domains such as ICT, Health & Pharma, and packaging. She is highly proficient in managing both B2C and B2B projects, with an emphasis on consumer preference analysis, key executive interviews, etc. When Kathleen isn’t deconstructing market performance trajectories, she can be found hanging out with her pet cat ‘Sniffles’.